The “Flolan Rash” | Great Cases from the JDD
INTRODUCTION
Epoprostenol (Flolan) is a last-resort intravenous (IV) medication for the treatment of severe pulmonary arterial hypertension (PAH). Cutaneous adverse events of Flolan are well-known by pulmonologists, though lacking in dermatologic literature.1 We report an extensive near erythrodermic appearing asymptomatic eruption following long-term use of epoprostenol. This characteristic and …
INTRODUCTION
Epoprostenol (Flolan) is a last-resort intravenous (IV) medication for the treatment of severe pulmonary arterial hypertension (PAH). Cutaneous adverse events of Flolan are well-known by pulmonologists, though lacking in dermatologic literature.1 We report an extensive near erythrodermic appearing asymptomatic eruption following long-term use of epoprostenol. This characteristic and … Continue reading "The “Flolan Rash” | Great Cases from the JDD"
The November issue of the Journal of Drugs in Dermatology (JDD) focuses on lasers, lights sources, and devices featuring original articles and case reports exploring topics such as combination of platelet rich plasma and 1550 nm fractional laser for androgenetic alopecia, safety of combination laser procedures in single clinic visit, efficacy of a fractionated 1540 nm erbium glass laser in the tre … 